Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 27.21% is 215% above its 5-year average of 8.65%, near the high end of its 5-year range (0.00%–27.21%).
As of the fiscal period ended Tuesday, June 30, 2026. 18.10% above its 12-month average of 23.04%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 27.21%.
DEBT TO ASSETS RATIO
27.21%
DEBT TO ASSETS RATIO AVG TTM
23.04%
DEBT TO ASSETS RATIO AVG 3Y
13.95%
DEBT TO ASSETS RATIO AVG 5Y
8.65%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+18.10%
CURRENT VS 3Y AVG
+95.11%
CURRENT VS 5Y AVG
+214.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12%
median of 395 covered companies
CURRENT VS SECTOR MEDIAN
+22577.51%
vs the sector median at left
Acumen Pharmaceuticals, Inc.
Market Cap
$153.84M
Debt to Assets Ratio
27.21%
TTM Avg
23.04%
3Y Avg
13.95%
5Y Avg
8.65%
Market Cap
$152.45M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$152.16M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.82M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$142.49M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$142.11M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$134.74M
Debt to Assets Ratio
0.36%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $153.84M | 27.21% | 23.04% | 13.95% | 8.65% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | 0.00% | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | 0.00% | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | 0.60% | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | 0.06% | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 0.20% | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | 0.00% | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | 0.36% | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | 0.05% | N/A | N/A | N/A |
Debt/Assets
27.2%
Debt/Equity
0.55
Current Ratio
2.47
Interest Coverage
-29.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 27.21% |
| 2026-03-31 | 23.32% |
| 2025-12-31 | 25.49% |
| 2025-09-30 | 21.68% |
| 2025-06-30 | 17.51% |
| 2025-03-31 | 14.18% |
| 2024-12-31 | 12.43% |
| 2024-09-30 | 11.23% |
| 2024-06-30 | 9.77% |
| 2024-03-31 | 9.29% |
| 2023-12-31 | 9.19% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.02% |
| 2023-03-31 | 0.04% |
| 2022-12-31 | 0.05% |
| 2022-09-30 | 0.07% |
| 2022-06-30 | 0.08% |
| 2022-03-31 | 0.09% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
